Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
RGLS's Cash to Debt is ranked higher than
78% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: 56.38 vs. RGLS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
RGLS' s Cash to Debt Range Over the Past 10 Years
Min: 1.76  Med: 9.29 Max: No Debt
Current: No Debt
Equity to Asset 0.84
RGLS's Equity to Asset is ranked higher than
73% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. RGLS: 0.84 )
Ranked among companies with meaningful Equity to Asset only.
RGLS' s Equity to Asset Range Over the Past 10 Years
Min: -1.26  Med: 0.72 Max: 0.89
Current: 0.84
-1.26
0.89
F-Score: 4
Z-Score: 2.38
M-Score: -3.33
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -371.10
RGLS's Operating margin (%) is ranked lower than
67% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: -72.99 vs. RGLS: -371.10 )
Ranked among companies with meaningful Operating margin (%) only.
RGLS' s Operating margin (%) Range Over the Past 10 Years
Min: -585.6  Med: -139.60 Max: -51.76
Current: -371.1
-585.6
-51.76
Net-margin (%) -366.42
RGLS's Net-margin (%) is ranked lower than
68% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: -75.29 vs. RGLS: -366.42 )
Ranked among companies with meaningful Net-margin (%) only.
RGLS' s Net-margin (%) Range Over the Past 10 Years
Min: -739.08  Med: -158.99 Max: -55.13
Current: -366.42
-739.08
-55.13
ROE (%) -49.06
RGLS's ROE (%) is ranked lower than
62% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. RGLS: -49.06 )
Ranked among companies with meaningful ROE (%) only.
RGLS' s ROE (%) Range Over the Past 10 Years
Min: -169.02  Med: -46.91 Max: -24
Current: -49.06
-169.02
-24
ROA (%) -42.92
RGLS's ROA (%) is ranked lower than
65% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. RGLS: -42.92 )
Ranked among companies with meaningful ROA (%) only.
RGLS' s ROA (%) Range Over the Past 10 Years
Min: -38.49  Med: -35.46 Max: -16.48
Current: -42.92
-38.49
-16.48
ROC (Joel Greenblatt) (%) -913.61
RGLS's ROC (Joel Greenblatt) (%) is ranked lower than
60% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -356.62 vs. RGLS: -913.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RGLS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1544.17  Med: -534.92 Max: -450.68
Current: -913.61
-1544.17
-450.68
Revenue Growth (3Y)(%) -36.10
RGLS's Revenue Growth (3Y)(%) is ranked lower than
82% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.40 vs. RGLS: -36.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RGLS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -89.60 Max: -36.1
Current: -36.1
EBITDA Growth (3Y)(%) -18.80
RGLS's EBITDA Growth (3Y)(%) is ranked lower than
68% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.10 vs. RGLS: -18.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RGLS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -73.70 Max: -18.8
Current: -18.8
EPS Growth (3Y)(%) -20.10
RGLS's EPS Growth (3Y)(%) is ranked lower than
67% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. RGLS: -20.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RGLS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -75.30 Max: -20.1
Current: -20.1
» RGLS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

RGLS Guru Trades in

RGLS Guru Trades in

Q2 2015

RGLS Guru Trades in Q2 2015

Jim Simons 57,000 sh (New)
» More
Q3 2015

RGLS Guru Trades in Q3 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with RGLS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:ATHX, AMEX:PFNX, NAS:DMTX, NAS:VTVT, OTCPK:HZNQF, OTCPK:MXDHF, NAS:QURE, NAS:NYMX, NAS:ARGS, OTCPK:VRACY, OTCPK:BBLG, OTCPK:SPHRF, NAS:CMRX, NAS:BOLT, OTCPK:CLVLF, NAS:MDWD, NAS:EGLT, OTCPK:EYRYY, NAS:CDXS, NAS:CARA » details
Traded in other countries:7RG.Germany,
Regulus Therapeutics Inc is a biopharmaceutical company. The Company is engaged in discovering and developing drugs that target micro RNAs to treat various diseases.

Regulus Therapeutics Inc was originally formed as a Delaware limited liability company under the name Regulus Therapeutics LLC on September 6, 2007. In January 2009, it converted Regulus Therapeutics LLC to a Delaware corporation and changed its name to Regulus Therapeutics Inc. The Company is a biopharmaceutical company engaged in discovering and developing first-in-class drugs that target microRNAs to treat various diseases. microRNAs are naturally occurring ribonucleic acid, or RNA, molecules that play a critical role in regulating key biological pathways. The Company has established Regulus microMarkers, a division engaged in identifying microRNAs as biomarkers of human disease, which is designed to support its therapeutic pipeline, collaborators and strategic partners. Through its microRNA target identification and validation efforts it has developed proprietary technologies for microRNA profiling and analysis of human clinical samples such as tissue. The Company has licensed patent rights from Julius-Maximilians-Universität Würzburg and Bayerische Patent Allianz GmBH, which rights encompass the use of anti-miR therapeutics targeting miR-21 for the treatment of fibrosis, including kidney, liver, lung and cardiac fibrosis. It has also license from Stanford University, or Stanford, to patent rights concerning the use of anti-miR therapeutics targeting miR-122 for the treatment of HCV infection. It has also licensed from ETH Zürich to patent rights related to the use of anti-miR therapeutics targeting miR-103/107 for the treatment of metabolic disorders, including type 2 diabetes. The Company's portfolio of exclusively and jointly owned patent and patent applications is currently composed of over 150 U.S. and foreign patents and patent applications with claims to compositions-of-matter or methods related to its microRNA drug products and microRNA product platform. The Company faces competition from other biotechnology and pharmaceutical companies. Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as those the Company is developing.

Ratios

vs
industry
vs
history
P/B 1.69
RGLS's P/B is ranked higher than
79% of the 1024 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. RGLS: 1.69 )
Ranked among companies with meaningful P/B only.
RGLS' s P/B Range Over the Past 10 Years
Min: 1.58  Med: 3.85 Max: 12.95
Current: 1.69
1.58
12.95
P/S 10.36
RGLS's P/S is ranked higher than
55% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 12.56 vs. RGLS: 10.36 )
Ranked among companies with meaningful P/S only.
RGLS' s P/S Range Over the Past 10 Years
Min: 0.1  Med: 18.98 Max: 111.09
Current: 10.36
0.1
111.09
EV-to-EBIT -1.22
RGLS's EV-to-EBIT is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 22.27 vs. RGLS: -1.22 )
Ranked among companies with meaningful EV-to-EBIT only.
RGLS' s EV-to-EBIT Range Over the Past 10 Years
Min: -24.9  Med: -7.40 Max: 3.1
Current: -1.22
-24.9
3.1
EV-to-EBITDA -1.25
RGLS's EV-to-EBITDA is ranked lower than
99.99% of the 304 Companies
in the Global Biotechnology industry.

( Industry Median: 18.12 vs. RGLS: -1.25 )
Ranked among companies with meaningful EV-to-EBITDA only.
RGLS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -25.9  Med: -7.80 Max: 3.2
Current: -1.25
-25.9
3.2
Current Ratio 10.51
RGLS's Current Ratio is ranked higher than
78% of the 903 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. RGLS: 10.51 )
Ranked among companies with meaningful Current Ratio only.
RGLS' s Current Ratio Range Over the Past 10 Years
Min: 1.64  Med: 9.24 Max: 12.36
Current: 10.51
1.64
12.36
Quick Ratio 10.51
RGLS's Quick Ratio is ranked higher than
78% of the 903 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. RGLS: 10.51 )
Ranked among companies with meaningful Quick Ratio only.
RGLS' s Quick Ratio Range Over the Past 10 Years
Min: 1.64  Med: 9.24 Max: 12.36
Current: 10.51
1.64
12.36
Days Sales Outstanding 1.31
RGLS's Days Sales Outstanding is ranked higher than
96% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 62.68 vs. RGLS: 1.31 )
Ranked among companies with meaningful Days Sales Outstanding only.
RGLS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.47  Med: 13.04 Max: 176.2
Current: 1.31
1.47
176.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.14
RGLS's Price/Net Cash is ranked higher than
82% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 4.94 vs. RGLS: 2.14 )
Ranked among companies with meaningful Price/Net Cash only.
RGLS' s Price/Net Cash Range Over the Past 10 Years
Min: 3.04  Med: 4.68 Max: 8.92
Current: 2.14
3.04
8.92
Price/Net Current Asset Value 1.91
RGLS's Price/Net Current Asset Value is ranked higher than
84% of the 829 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. RGLS: 1.91 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
RGLS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.87  Med: 4.45 Max: 8.11
Current: 1.91
2.87
8.11
Price/Tangible Book 1.70
RGLS's Price/Tangible Book is ranked higher than
82% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. RGLS: 1.70 )
Ranked among companies with meaningful Price/Tangible Book only.
RGLS' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.74  Med: 4.26 Max: 7.36
Current: 1.7
2.74
7.36
Price/Median PS Value 0.54
RGLS's Price/Median PS Value is ranked higher than
79% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: 0.94 vs. RGLS: 0.54 )
Ranked among companies with meaningful Price/Median PS Value only.
RGLS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.01  Med: 1.12 Max: 4.86
Current: 0.54
0.01
4.86
Earnings Yield (Greenblatt) (%) -82.00
RGLS's Earnings Yield (Greenblatt) (%) is ranked lower than
90% of the 1104 Companies
in the Global Biotechnology industry.

( Industry Median: -9.68 vs. RGLS: -82.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RGLS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 32.8  Med: 39.35 Max: 44.4
Current: -82
32.8
44.4

More Statistics

Revenue (TTM) (Mil) $17.05
EPS (TTM) $ -1.19
Beta1.71
Short Percentage of Float13.27%
52-Week Range $2.44 - 10.60
Shares Outstanding (Mil)52.78

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 2 2 2
EPS ($) -1.61 -1.85 -2.21
EPS w/o NRI ($) -1.61 -1.85 -2.21
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for RGLS

Headlines

Articles On GuruFocus.com
Top Insider Buys, Sells of the Week Feb 26 2016 
Weekly CEO Sells Highlight: Hovnanian Enterprises Inc, Regulus Therapeutics Inc, Monster Beverage Co Apr 27 2015 
Regulus Therapeutics (RGLS) microRNA Therapeutic Milestone Payment, Dave & Buster's Entertainment (P Apr 08 2015 
This Week’s Pharma Highlights Mar 19 2015 
Weekly CEO Sells Highlight: Kimberly-Clark Corp, Regulus Therapeutics Inc, Prologis Inc, and Adobe S Feb 01 2015 

More From Other Websites
Regulus to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference Jul 05 2016
4 Companies That Destroyed Shareholders Despite a Brexit Recovery Jul 03 2016
The Zacks Analyst Blog Highlights: Gilead, Regulus, AbbVie, The Medicines and GW Pharma Jun 30 2016
Biotech Stock Roundup: Gilead Gets FDA Nod for HCV Drug, Regulus Hit by Clinical Hold Jun 29 2016
Fitbit, Regulus Join Tuesday’s 52-Week Low Club Jun 28 2016
INVESTOR NOTICE: Lundin Law PC Announces Investigation Of Regulus Therapeutics Inc. And Advises... Jun 28 2016
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Regulus... Jun 28 2016
Why Are These Stocks Deep in Red Today? Jun 28 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into... Jun 28 2016
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Regulus... Jun 28 2016
Why Regulus Is Tanking Jun 28 2016
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regulus... Jun 28 2016
Regulus Therapeutics' stock set to fall after FDA places hepatitis C treatment on hold Jun 27 2016
REGULUS THERAPEUTICS INC. Files SEC form 8-K, Other Events Jun 27 2016
Regulus Reports Clinical Hold of RG-101 Jun 27 2016
ETF’s with exposure to Regulus Therapeutics, Inc. : June 27, 2016 Jun 27 2016
REGULUS THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation... Jun 23 2016
Regulus Secures $30 Million Growth Capital Credit Facility Jun 20 2016
REGULUS THERAPEUTICS INC. Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders Jun 14 2016
REGULUS THERAPEUTICS INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Jun 08 2016
Regulus to Present at the Jefferies 2016 Healthcare Conference Jun 03 2016
Dr. Hugh Rosen Joins Regulus Board of Directors Jun 02 2016
Regulus Expands Clinical Trial Collaboration with GSK Jun 01 2016
Regulus Appoints Allison Wey as Vice President, Investor Relations & Corporate Communications May 23 2016
Regulus to Present New RG-012 Data at The 53rd European Renal Association-European Dialysis and... May 20 2016
Regulus to Present at the 2016 UBS Global Healthcare Conference May 18 2016
Regulus to Present at the Bank of America Merrill Lynch 2016 Healthcare Conference May 04 2016
Regulus reports 1Q loss May 02 2016
Regulus Reports First Quarter 2016 Financial Results and Recent Highlights May 02 2016
Regulus Announces Timing for First Quarter 2016 Financial Results Webcast and Conference Call Apr 26 2016
Regulus Presents Additional Interim Data on RG-101 at International Liver Congress™ (ILC 2016) Apr 15 2016
Regulus reports 4Q loss Feb 22 2016
Regulus Completes RG-101 Enrollment in Phase II Combination Study Jan 21 2016
Regulus Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Jan 06 2016
RG-125(AZD4076), a microRNA Therapeutic Targeting microRNA-103/107 Being Developed for the Treatment... Dec 18 2015
Regulus Appoints Joseph P. Hagan Chief Operating Officer Dec 07 2015
Regulus Announces Grant of Patents Covering Lead microRNA Therapeutics Nov 12 2015
Regulus reports 3Q loss Nov 05 2015
Regulus Reports Third Quarter 2015 Financial Results and Recent Highlights Nov 05 2015
GSK plan to file up to 20 new drugs by 2020 underwhelms market Nov 03 2015
Regulus Expands Development of RG-101 through Clinical Trial Collaboration with GSK Nov 03 2015
Regulus Announces Timing for Third Quarter 2015 Financial Results Webcast and Conference Call Oct 29 2015
Regulus Achieves All Research Milestones in Collaboration with Biogen to Identify microRNA... Oct 28 2015
Regulus to Present Additional Preclinical Data Supporting RG-012 as a Novel microRNA Therapeutic in... Oct 05 2015
Regulus reports 2Q loss Aug 04 2015
Regulus reports 1Q loss May 07 2015
Regulus reports 4Q loss Feb 18 2015
Regulus misses Street 3Q forecasts Nov 05 2014
Regulus surges on early hepatitis C drug data Oct 22 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)